(MENAFN- Investor Brand Network) The Japanese government recently announced that the coronavirus will be
categorized as a common infectious disease on may 8, 2023.
As a result, patients diagnosed with the communicable disease will have to cover medical expenses on their own.
In the wake of the coronavirus pandemic in 2020, Japan's government instituted a special response that limited the number of...
NOTE TO INVESTORS:
The latest news and updates relating to BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) are available in the company's newsroom at
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via
to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with
bmw prime . As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text“Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit
San Francisco, California
BioMedWire is part of the
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.